Therapeutic Efficacy of Platinum/Etoposide Regimens in the Treatment of Advanced Poor Differentiated Neuroendocrine Carcinomas of the Lung: A Retrospective Analysis


Introduction: Advanced neuroendocrine carcinomas (NEC) of the lung are associated with a dismal prognosis and are commonly treated with platinum/etoposide (P/E) regimens. However, few studies evaluated their impact in lung NEC and it is still unclear whether the outcome of such patients (pts) has been improved over the past years (yrs).

Aim(s): The aim of our study was to evaluate the outcome of advanced lung NEC pts treated with P/E at two Italian institutions.

Materials and methods: We retrospectively evaluated 68 consecutive pts with histological-confirmed advanced small cell lung cancer (SCLC) or large cell NEC of the lung (LCNEC) treated with P/E over 10 yrs (Sep 2006 - Dec 2016). Clinic-pathologic characteristics, treatments, and outcome of all pts were collected. Survival curves were estimated using the Kaplan–Meier method and compared with the log-rank test.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Giuffrida D

Authors: Giuffrida D, Chillari F, Blanco G, Russo A, Franchina T,

Keywords: neuroendocrine carcinoma, lung, platinum-etoposide, LCNEC, SCLC, chemotherapy,

To read the full abstract, please log into your ENETS Member account.